William Belles, MD
Plastic Surgery within the Head & Neck · Tonawanda, NYNPI 1346275286
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,200 of the $15,228 with a category attached, or 60.4%. GSK accounts for 65.7% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $5,762 and has fallen 89.3% since, to $617 in 2025. Among plastic surgery within the head & neck clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $67.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$10K
- Aerin Medical Inc.$2K
- Optinose US, Inc.$586
- Sanofi$468
- Inspire Medical Systems, Inc.$413
- Medtronic$315
- plus $2K from 14 others
What the payments were for
- Speaking & faculty fees$9,20060%
- Travel & lodging$1,2298%
- Food & beverage$4,79932%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 46 | $10,000 |
| Aerin Medical Inc. | 29 | $1,925 |
| Optinose US, Inc. | 57 | $586 |
| Sanofi | 35 | $468 |
| Inspire Medical Systems, Inc. | 4 | $413 |
| Medtronic | 5 | $315 |
| Alk-abello, Inc | 9 | $259 |
| AstraZeneca | 9 | $234 |
| Stryker | 4 | $194 |
| Intersect ENT, Inc. | 9 | $186 |
| Regeneron Healthcare Solutions, Inc. | 8 | $175 |
| Smith+Nephew | 1 | $125 |
| Acclarent, Inc | 1 | $123 |
| Integra Lifesciences Corporation | 2 | $58 |
| KARL Storz Endoscopy-america | 2 | $45 |
| Amgen(2 entities) | 2 | $37 |
| Johnson & Johnson | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$9,314
- VIVAER STYLUS$1,378
- RHINAER STYLUS$461
- Inspire Upper Airway Stimulation System$332
- PROPEL$136
- TULA$125
- TruDi Nav Cable$123
- PTEYE PARATHYROID DETECTION SYSTEM$118
- Odactra$115
- XPRESS ENT DILATION SYSTEM$114
How this compares
$15,228 in reported general payments places this provider in the 90th percentile of 45 plastic surgery within the head & neck providers in New York.
See all plastic surgery within the head & neck providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 69 | $257,750 |
| XhanceFluticasone Propionate | 37 | $36,133 |
| Cevimeline Hcl | 100 | $14,456 |
| Mometasone Furoate | 181 | $6,691 |
| Fluticasone Propionate | 343 | $5,342 |
| Ipratropium Bromide | 125 | $4,815 |
| Azelastine Hcl | 158 | $4,411 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 62 | $2,826 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 15 | $2,312 |
| Levothyroxine Sodium | 51 | $1,927 |
| Prednisone | 239 | $1,491 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 47 | $1,263 |
| Doxycycline Hyclate | 42 | $1,186 |
| Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort | 19 | $1,167 |
| Famotidine | 33 | $1,099 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $586 | $36,13337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 45 plastic surgery within the head & neck providers in New York.
Other plastic surgery within the head & neck in Tonawanda
- Robert SchwarczNew York$188K
- James MarottaSmithtown$69K
- Roger KatzSyosset$28K
- Robert LohmanBuffalo$21K
- Eric CohenNew York$9K
- Anthony AlessiValhalla$7K
- Erich VoigtNew York$6K
- George BraunNew York$4K
- Adrian OngNew York$3K
- Thomas RomoNew York$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.